New Delhi, Feb 21 (UNI) Aurobindo Pharma Ltd today said DRU (Drugs regulatory unit) of Botswana has registered nine of its anti retro viral (ARV) products at a single time.
These products are used extensively in the treatment of HIV positive patients.
The products include Lamivudine and Zidovudine tablet, Zidovudine oral solution 50 mg/5 ml, Nevirapine Oral Suspension 50 mg/ml, Lamivudine oral solution 10 mg/ml, Nevirapine 200 mg tablet, Stavudine 30 mg capsules, Stavudine 40 mg capsules, Lamivudine 150 mg tablets and Lamivudine 300 mg tablets.
Botswana is a key market for ARVs, hence these registrations with the authorities would help the company to consolidate its position in the said market, a statement said.
UNI
These products are used extensively in the treatment of HIV positive patients.
The products include Lamivudine and Zidovudine tablet, Zidovudine oral solution 50 mg/5 ml, Nevirapine Oral Suspension 50 mg/ml, Lamivudine oral solution 10 mg/ml, Nevirapine 200 mg tablet, Stavudine 30 mg capsules, Stavudine 40 mg capsules, Lamivudine 150 mg tablets and Lamivudine 300 mg tablets.
Botswana is a key market for ARVs, hence these registrations with the authorities would help the company to consolidate its position in the said market, a statement said.
UNI
Oneindia Login